Tenax Therapeutics Inc. said it regained compliance with the Nasdaq Capital Market's minimum bid price requirement of $1 per share.
The Morrisville, N.C.-based specialty pharmaceutical company implemented a 1-for-20 reverse stock split of its common shares to regain compliance with Nasdaq's listing rule.
